3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Interventions
Imatinib Mesylate
6
Laparoscopy
3
Surgical Procedures, Operative
2
spartalizumab
1
ripretinib
1
regorafenib
1
ponatinib
1
famitinib
1
apixaban
1
anlotinib
1
Thoracic Surgery, Video-Assisted
1
TH 302
1
Surveys and Questionnaires
1
Surgical Tape
1
Sunitinib
1
Rivaroxaban
1
Oxaliplatin
1
Nivolumab
1
Liver Transplantation
1
Ipilimumab
1
Interviews as Topic
1
Endoscopic Mucosal Resection
1
Dasatinib
1
Dalteparin
1
Blood Specimen Collection
1
Biopsy
1
68Ga-NOTA-RM26
1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gastrointestinal Stromal Tumors
×
ponatinib
×
Clear all
NCT03171389
2017-05-31
POETIG
Universität Duisburg-Essen
Phase 2
Unknown
81 enrolled